INBS

Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first-half performance Gross profit margin expands to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month period NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal third quarter and nine months ended March 31, 2026, and provided a business update. "The third quarter marked another period of strong commercial execution and revenue growth," said Harry Simeonidis, President and CEO at INBS. "Cartridge revenue increased 59% year-over-year and accounted for 66% of Q3 revenue, confirming that customer utilization patterns align with our recurring revenue, razor-razorblade business model. Nine-month revenue of $3.07 million reflects consistent and compounding growth, and the business is continuing to strengthen ahead of important FDA regulatory milestones and our anticipated entry into the multi-billion-dollar U.S. market." "Our results this quarter and over the past nine months demonstrate that we are delivering on our core business fundamentals," said Spiro Sakiris, CFO at INBS. "Q3 gross margin was over 50%, up from 47% a year ago. This growth was driven by operational efficiencies and increased sales volumes. Our value-driven pricing structure has also remained consistent, as customers recognize the efficiency and cost-effectiveness of our fingerprint drug screening technology compared to traditional methods. Our nine-month marketing investment of $1.77 million has been a direct contributor to our 39% revenue growth and successful capital raising of $14.67 million (net of issuance costs), and we are now seeing improved marketing efficiency in Q3, with the quarter’s spend down 42% year-over-year while commercial momentum continues to accelerate." Product Revenue Breakdown Three Months Ended March 31, 2026 (Q3 Fiscal 2026): Cartridge sales of $703,538, up 59% year-over-year, representing 66% of Q3 revenue Reader sales of $139,407, declined 16% year-over-ye...

Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach $1.62 billion by 2030 NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of a validation study aimed at significantly reducing the analysis time of its Intelligent Fingerprinting Drug Screening System. The study aims to improve the already rapid time-to-result of INBS's drug screening technology, which collects samples in under a minute and provides results within ten minutes at the point of collection. Faster results will enable INBS to target the global roadside drug testing market with a first-in-class solution. "Speed matters in drug screening and is critical for roadside law enforcement,” said Harry Simeonidis, President and CEO at INBS. “Moving from a ten-minute test to under three minutes changes the entire value equation for our customers. This validation study aims to confirm our encouraging preliminary findings and advance us toward our two-minute test goal.” In the U.S. alone, roadside drug testing was valued at $1.17 billion in 2023 and is projected to reach $1.62 billion by 2030, growing at a compound annual growth rate of 4.71%1. The rise in prescription medications, recreational marijuana, and illicit drugs has created a surge in drug-related accidents and fatalities. Law enforcement agencies are intensifying efforts to combat impaired driving, creating demand for advanced testing solutions that deliver quick, accurate field results. INBS's system is already deployed in the Forensic Use Only market in the U.S., and enhanced speed would further strengthen the technology’s positioning as states expand drug testing programs following marijuana legalization and increased substance abuse concerns. Faster analysis times have the potential to transform roadside drug testing in the same way that breathalyzers revolutionized alcohol enforcement. Increased testing throughput will enable law enforcement to screen more drivers, improving road safety and potentially saving lives. In addition to roadside applications, accelerated testing would further expand INBS's access to other h...

First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal second quarter and six months ended December 31, 2025, and provided a business update. "Our second quarter figures demonstrate consistency and solid progress across our business,” said Harry Simeonidis, President and CEO of INBS. “Reader sales more than doubling shows market demand for our non-invasive fingerprint drug testing technology and significantly expands our installed base, the engine for future recurring revenue. Equally important is the 33% growth in cartridge sales, which confirms existing customers are actively using our system and reordering consumables. This is our razor-razorblade model working as designed - hardware placements create the foundation, and consumable sales deliver ongoing revenue. With strong year-over-year growth and first-half revenue exceeding $2 million, we're building sustainable momentum as we advance our regulatory pathway toward planned U.S. market entry." "We are seeing the financial model take shape as intended,” said Spiro Sakiris, CFO of INBS. “104% reader growth in fiscal Q2 is building our installed base, while 33% cartridge growth shows our recurring revenue model gaining traction. We did not get here by chance. These achievements are the result of deliberate, strategic marketing investment aimed at enhancing our market awareness. Our operating expense control and revenue scaling are creating the operational leverage we've been targeting. This is complemented by the $9.40 million net proceeds from the private placement of our securities, which funds were received on January 2, 2026, and strongly capitalized our balance sheet....

Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal second quarter and first half 2026 ended December 31, 2025. The Company expects to report strong revenue growth across all product categories for the three- and six-month periods ended December 31, 2025. Six-Month Period (Fiscal H1 ’26, July - December 2025): Total revenue expected to be approximately $2.01 million, representing a 36% increase year-over-year Sales of cartridges expected to increase approximately 38% year-over-year Sales of readers expected to increase approximately 50% year-over-year Other sales (accessories, training) expected to increase approximately 10% year-over-year Three-Month Period (Fiscal Q2 ’26, October - December 2025): Revenue expected to increase approximately 48% year-over-year Sales of cartridges expected to increase approximately 33% year-over-year Sales of readers expected to more than double, increasing approximately 104% year-over-year Other sales (accessories, training) expected to increase approximately 36% year-over-year “We are very pleased with our expected results, showing strong second-quarter performance and reader sales more than doubling year-over-year," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "This expansion of our installed base is the foundation of our razor-razorblade business model, as each reader placement creates a long-term relationship that drives recurring cartridge revenue. The anticipated 33% growth in cartridge sales demonstrates this model in action, reflecting new customer adoption and ongoing consumable demand. Momentum across all product categories reinforces our confidence in the commercial strategy and our ability to capture greater market share. As our installed reader base continues to grow, we are strengthening the foundation for recurring revenue growth throughout fiscal 2026 and beyond." The preli...

Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first quarter delivered record quarterly revenue of $1.11 million, driven by accelerating cartridge sales, significant customer acquisition, and strategic partnerships that position INBS for continued expansion across key international markets. The Company's consumable-focused business model demonstrated strong momentum, with cartridge sales representing nearly 58% of total revenue. Gross profit margins increased by 690 basis points year-over-year to 46.6%, due to improved operational efficiency and a greater revenue percentage from higher margin cartridge sales. "Our first quarter results show accelerating momentum of our business model and the growing market adoption internationally of our non-invasive drug screening technology," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "We achieved record quarterly revenue of $1.11 million, representing our strongest quarter to date, with 32% growth sequentially and 28% year-over-year. This significant revenue increase, combined with expanding gross margins, validates our strategic focus on consumable cartridge sales and positions us well for sustained growth as we advance along the regulatory pathway toward planned FDA clearance and U.S. market entry." Key Financial and Operational Highlights Revenue of $1,111,797, up 32% sequentially from the fiscal fourth quarter 2025 and 28% year-over-year from the fiscal first quarter 2025. Cartridge sales of $640,300 represented 57.59% of total revenue, up from 51.1% in the fiscal first quarter of 2025, demonstrating the strength of the Company's recurring revenue model. Gross profit margins increased to 46.6% from 39.68% in the fiscal first quarter of 2025, reflecting improv...

Company Achieves Third Consecutive Quarter of Revenue Growth Revenue Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New Customer Accounts and Strong Cartridge and Reader Sales Cartridge and Reader Revenue Up Approximately 43% and 23% Year-Over-Year Respectively NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal first quarter ended September 30, 2025. “We started fiscal year 2026 on a strong note, generating over $1 million in revenue - a record for our Company and a significant milestone,” said Harry Simeonidis, President and CEO of Intelligent Bio Solutions. “As new customer acquisitions accelerate, we are seeing strong momentum in both cartridge and reader sales, with cartridge revenue up approximately 43% year-over-year and reader revenue up approximately 23% year-over-year for the fiscal first quarter. These results represent a substantial improvement on the previous quarter, demonstrating the strength of our business model and positioning us well for continued growth.” The Company expects to report fiscal first quarter 2026 revenue growth of approximately 32% sequentially and 28% year-on-year. This represents the third consecutive quarter of revenue growth and shows the strength of the Company’s razor-razorblade business model. The anticipated results reflect ongoing enhancements in the Company’s sales mix, with higher-margin consumables continuing to account for an increasing share of total revenue. The preliminary unaudited revenue results for the fiscal first quarter ended September 30, 2025, are based on information available to management as of the date of this press release and are, therefore, subject to adjustments based on the Company’s completion of its quarter-end financial close process. The Company expects to disclose financial results for the fiscal first quarter ended September 30, 2025, in its upcoming Quarterly Report on Form 10-Q, expected to be filed with the Securities and Exchange Commission during the week commencing November 10, 2025. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, n...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025, representing a 50% increase compared with the same period the prior year. The continued growth brings the Company’s total number of active accounts to over 480, demonstrating sustained customer expansion and revenue momentum. Year-over-year analysis, based on full-year figures, highlights the strongest growth in customer acquisition within the maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration sectors. Notably, government administration represents a newly entered sector, emphasizing the expanding applicability of INBS's solutions across both public and private domains where operational safety and compliance are critical. "Our expanding customer base demonstrates increasing confidence in our technology and the growing recognition of its value proposition. As we move toward the second quarter of fiscal year 2026, our focus remains on converting this momentum into sustained revenue growth and long-term value," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "Our fingerprint-based drug testing technology is helping organizations streamline screening, minimize downtime, and enhance compliance, delivering measurable operational and economic benefits." Growth was particularly strong in the United Kingdom, supported by expanding distributor activity across Europe and the Middle East. Approximately 91% of new accounts were first-time adopters of INBS's drug screening solution, while the remaining 9% represented expansion within existing customer organizations, highlighting the Company's ability to attract new users and deepen engagement among its established customer base. "Adoption is broadening across new and existing customers," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. “More industries are recognizing the operational value of our solution, and existing customers are scaling use as confidence in its accuracy and reliability strengthens." The global drug screening market is projected to reach USD 17.1...

Explore Intelligent Bio Solutions's Fair Values from the Community and select yours Revenue: US$3.05m (down 1.9% from FY 2024). Net loss: US$10.6m (loss widened by 4.1% from FY 2024). US$2.00 loss per share. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Intelligent Bio Solutions shares are down 3.3% from a week ago. Don't forget that there may still be risks. For instance, we've identified 6 warning signs for Intelligent Bio Solutions (3 don't sit too well with us) you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Fiscal 2025 marked a year of growth for the Company, driven by higher-margin cartridge sales, operational streamlining, and regulatory advancements that support future expansion in the U.S. market, beyond current Forensic Use Only settings. The Company continues to expand its commercial presence internationally, with an active customer base exceeding 450 accounts across 24 countries, and 18 distribution partners. “Fiscal 2025 was a pivotal year for our business as we continued to lay the foundation for global growth,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “We delivered sequential growth over fiscal quarters three and two, driven by increased cartridge revenue, improved operational discipline, and growing international momentum. As we enter fiscal 2026, we’re focused on three strategic priorities: further accelerating growth, advancing operational excellence, and expanding beyond Forensic Use Only settings in the U.S. Our FDA regulatory pathway remains on track, and we are committed to achieving FDA clearance to expand into the U.S., the world’s largest drug screening market, and deliver our non-invasive solution to more organizations seeking fast, dignified, and reliable testing alternatives.” Progress Toward FDA Clearance and U.S. Market Expansion INBS remains focused on securing FDA 510(k) clearance for its opiate test system for codeine in the U.S., enabling broader use beyond current Forensic Use Only settings. In fiscal 2025, the Company advanced its regulatory strategy through increased engagement with regulatory consultants, refined clinical study design, and the generation of new scientific and clinical data to support its submission. The Company's submission to the FDA was supported by a comprehensive dataset comp...

Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and strengthened global readiness through system upgrades and localization NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results and key operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. "Fiscal 2025 represented a year of disciplined execution and strategic investment. For the fiscal fourth quarter, we expect to report another quarter of sequential and year-over-year revenue growth." said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "In addition to our strong revenue performance, during the quarter we also made significant progress on the regulatory pathway in seeking U.S. FDA 510(k) clearance and continued scaling our operations globally with system upgrades and localization." The Company expects to report fiscal fourth quarter 2025 revenue increases of approximately 16% sequentially and year-over-year, reflecting continued demand for its higher-margin cartridge sales and steady account growth. Preliminary results indicate sequential revenue growth over both the fiscal third and second quarters. Operational Highlights Submitted FDA 510(k) application for its opiate test system for codeine, supported by new scientific and clinical validation data. Completed multilingual upgrades to the Intelligent Fingerprinting Drug Screening System, supporting broader global adoption. Launched localized websites and enhanced CRM workflows to improve partner and end-user engagement across Europe, the Middle East, and Latin America. The preliminary unaudited revenue results for the fiscal fourth quarter and full year ended June 30, 2025, are based on information available to management as of the date of this press release and are, therefore, subject to adjustments based on the Company’s completion of its year-end financial close process. The Company expects to disclose financial results for the fiscal fourth quarter and fiscal year ended June 30, 2025, in its upcoming Annual Report on Form 10-K, expected to be filed w...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 13, 2025 (NEWMEDIAWIRE) - Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company delivering rapid, non-invasive testing solutions, reported a 20% sequential revenue increase to $728,867 in fiscal Q3 2025, driven by growth in cartridge sales, which now account for 58% of total revenue and strengthen its recurring revenue model. Gross profit surged 91% year-over-year to $341,368, while net loss narrowed by $434,141 to $2.54 million. INBS added 35 new accounts, bringing its active customer base to over 450, and continued expanding internationally through partnerships and multilingual system upgrades. The company also secured its sixth U.S. patent and advanced regulatory efforts across key global markets. To view the full press release, visit https://ibn.fm/V56hu About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer The latest news and updates relating to INBS are available in the company's newsroom at h...

20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update. The Company delivered a strong quarter of growth in revenue compared to the previous quarter, supported by ongoing expansion across safety-critical industries and steady customer acquisition. Cartridge sales, a key contributor to margin improvement, continue to make up a growing share of income, contributing 58% of total revenue for the fiscal year to March 31, 2025, and strengthening the Company’s recurring revenue model. With 35 new customers added during the quarter and an active customer base now surpassing 450 accounts, INBS remains on track with its plans to scale its commercial footprint and international presence ahead of its expected entry into the U.S. market. During the fiscal third quarter, the Company advanced its international growth strategy and product readiness through a series of targeted initiatives. These included expanded access in key European markets, multilingual upgrades to its drug screening system and digital outlets, and further protection of its core intellectual property portfolio. Together, we believe these developments support the Company’s ability to scale globally and drive sustained commercial growth. “As we expand further into new markets, our focus on growing cartridge adoption, our highest-margin revenue stream, is strengthening the business fundamentals,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “We’ve also seen a notable reduction in losses this quarter, reflecting ongoing improvements in cost control and operational efficiency. To support global scalability, we introduced multilingual functionality across our drug screening system and websites, ensuring our solution is widely accessible, commercially viable, and ready for broader distr...